Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
- HAEMOPHILUS B CONJUGATE VACCINE (MENINGOCOCCAL PROTEIN CONJUGATE)
- haemophilus b conjugate vaccine meningococcal protein conjugate
- HAEMOPHILUS INFLUENZAE B (ROSS STRAIN) CAPSULAR POLYSACCHARIDE MENINGOCOCCAL PROTEIN CONJUGAT
- haemophilus influenzae b ross strain capsular polysaccharide meningococcal protein conjugat
- haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen
- Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen
- haemophilus influenzae type b polysaccharide conjugate antigen c
- HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE CONJUGATE ANTIGEN, C
- pedvaxhib
- Pedvaxhib
- PedvaxHIB
- PedvaxHIB®
- PedvaxHIB™
- First in class
- No
- Orphan designation
- No
Reported adverse events
- Event
- interchange of vaccine products
- Reports
- 1
- Reporting signal score
- 11.576
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (35)
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
- A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.
- A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults
- Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants
- Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants
- Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth
- Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
- Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV
- Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib
- Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)
- DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants
- Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
- Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
- Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
- Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine
- Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)
- Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
- Influence of Inflammation on Micronutrient Status Assessment